Literature DB >> 11884519

Proprotein convertases are important mediators of the adipocyte differentiation of mouse 3T3-L1 cells.

Gilles Croissandeau1, Ajoy Basak, Nabil G Seidah, Michel Chrétien, Majambu Mbikay.   

Abstract

Mouse 3T3-L1 cells are widely used to study adipocyte differentiation in vitro. When treated with insulin, dexamethasone and isobutylmethylxanthine these fibroblastic cells differentiate into round triglyceride-rich adipocytes. Because several proteins implicated in adipocyte differentiation (e.g. type 1 IGF receptors) are proteolytically activated by endoproteinases of the proprotein convertase family, we sought to determine whether these endoproteinases are crucial for adipose conversion. In this study, we show that expression of the proprotein convertases PACE4, PC7 and furin increases when 3T3-L1 cells are induced to differentiate into adipocytes. The differentiation was blocked in transfected cells expressing alpha1-antitrypsin Portland or in normal cells pre-treated with the synthetic inhibitor decanoyl-RVKR-chloromethylketone. Both inhibitors are known to specifically inactivate proprotein convertases. The block was associated with impaired proteolytic activation of proIGF-1 receptor, absence of induction of the adipogenic transcriptional factor PPARgamma and marked reduction of the nuclear translocation of the C/EBPbeta factor. Taken together, these data constitute evidence that proprotein convertases are crucial mediators of adipogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884519     DOI: 10.1242/jcs.115.6.1203

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  8 in total

1.  Enhanced insulin secretion from engineered 3T3-L1 preadipocytes by induction of cellular differentiation.

Authors:  Kei Fujimoto; Takashi Sasaki; Masami Nemoto; Nozomu Nakai; Kyoko Sakai; Koichiro Yamasaki; Yoshito Hiki; Toya Ohashi; Yoshikatsu Eto; Naoko Tajima
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 2.  Inhibitors of proprotein convertases.

Authors:  Ajoy Basak
Journal:  J Mol Med (Berl)       Date:  2005-10-08       Impact factor: 4.599

3.  Involvement of matrix metalloproteinases in the adipose conversion of 3T3-L1 preadipocytes.

Authors:  Gilles Croissandeau; Michel Chrétien; Majambu Mbikay
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

4.  Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study.

Authors:  Ron C Hoogeveen; John W Gaubatz; Wensheng Sun; Rhiannon C Dodge; Jacy R Crosby; Jennifer Jiang; David Couper; Salim S Virani; Sekar Kathiresan; Eric Boerwinkle; Christie M Ballantyne
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-20       Impact factor: 8.311

5.  Surface expression and limited proteolysis of ADAM10 are increased by a dominant negative inhibitor of dynamin.

Authors:  Robyn M Carey; Jan K Blusztajn; Barbara E Slack
Journal:  BMC Cell Biol       Date:  2011-05-17       Impact factor: 4.241

6.  PCSK7 genotype modifies effect of a weight-loss diet on 2-year changes of insulin resistance: the POUNDS LOST trial.

Authors:  Tao Huang; Jinyan Huang; Qibin Qi; Yanping Li; George A Bray; Jennifer Rood; Frank M Sacks; Lu Qi
Journal:  Diabetes Care       Date:  2014-12-12       Impact factor: 19.112

7.  Proprotein convertase subtilisin/kexin type 3 promotes adipose tissue-driven macrophage chemotaxis and is increased in obesity.

Authors:  Kai Kappert; Heike Meyborg; Jan Fritzsche; Daniel Urban; Janine Krüger; Ernst Wellnhofer; Ulrich Kintscher; Eckart Fleck; Philipp Stawowy
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

8.  PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.

Authors:  Frédéric Couture; Christine Levesque; Véronique Dumulon-Perreault; Samia Ait-Mohand; François D'Anjou; Robert Day; Brigitte Guérin
Journal:  Neoplasia       Date:  2014-08       Impact factor: 5.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.